100 Key Veterinary Medicines With Estimated Sales, 2018 - 2022

Report Overview

The animal health research team at Grand View Research has compiled a quantitative and qualitative database of about 100 Key Veterinary Medicines. These comprise leading pharmaceuticals, biologics, and medicated feed additives that are major revenue generators for their companies. The database includes best-selling animal health molecules spanning antiparasitic (parasiticides), anti-infectives, antibiotics, anti-inflammatory, anti-emetic, and dermatology categories. Some of the molecules (INN) covered in the database include Oclacitinib maleate, Lokivetmab, Selamectin, Amoxicillin, Ivermectin, and Pyrantel. The dataset is provided in Excel format and covers top animal health manufacturers such as Zoetis, Virbac, Elanco, Dechra, Merck, Boehringer Ingelheim International GmbH, Phibro Animal Health, and Neogen Corporation.

For instance, Oclacitinib maleate sold under the brand name-Apoquel by Zoetis, is the first Janus kinase inhibitor approved for use in veterinary medicine. The product is a high revenue generator for the company owing to its patent and continuous product advancements. In 2021, for instance, a chewable version of Apoquel received clearance in the UK and the European Union (EU). Another key product of the company, however, continued to be negatively impacted by generic competition during 2019 and 2020 in the U.S. The database thus intends to give an idea about leading veterinary medicinal products in the market and key information about these products such as patent information, competition from generics, ASP, and regulatory approvals.

Key Veterinary Medicine Report Scope

Competitive Landscape

Zoetis, Virbac, Elanco, Merck, Dechra, Boehringer Ingelheim International GmbH, Phibro Animal Health, and Neogen Corporation are among the market leaders in the animal health domain. These companies have a diverse portfolio of veterinary medicines, diagnostic products, services, and software catering to veterinarians, pet owners, other animal health companies, etc. These companies continuously boost their market position with various strategic initiatives such as the launch of new products, partnerships, regional expansion, mergers & acquisitions, and R&D.

The robust market presence, patent grants, and extensive portfolio of these companies contribute to their high revenues. For example, Boehringer Ingelheim’s top 4 animal health products resulted in net sales of over USD 2.4 billion in 2023. Zoetis on the other hand reported 13 blockbuster products among its wide product lineup that contributed over USD 100 million each in sales in 2019. By 2023, the company’s top 10 best-selling product lines attributed to 49% of its total sales. This represents a growing animal health market that presents lucrative opportunities for the coming years for those willing to leverage emerging trends.